The effect of SARS-CoV-2 mRNA vaccination on AMH concentrations in infertile women. Issue 4 (October 2022)

• Record Type: Journal Article
• Authors: Horowitz, Eran; Mizrachi, Yossi; Ganer Herman, Hadas; Oz Marcuschamer, Einat; Shalev, Amir; Farhi, Jacob; Barber, Elad; Orna, Schwartz Harari; Raziel, Arieh; Weissman, Ariel
• Is Part Of: Reproductive biomedicine online. Volume 45:Issue 4(2022)
• Page Start: 779
• Page End: 784
• Publication Date: 2022-10
• Subjects: Anti-Müllerian hormone -- COVID-19 -- Fertility -- Ovarian reserve -- SARS-CoV-2 mRNA vaccine; Human reproductive technology -- Periodicals; Human embryo -- Periodicals; Reproduction -- Periodicals; 616.692
• DOI: 10.1016/j.rbmo.2022.06.015
• Languages: English
• ISSNs: 1472-6483

Abstract

ABSTRACT: Research question: Does SARS-CoV-2 mRNA vaccination affect the ovarian reserve of infertile women undergoing IVF? Design: This was a prospective observational study at a single university-affiliated IVF unit that included infertile women aged 18–44 years who were undergoing IVF/intracytoplasmic sperm injection between November 2020 and September 2021, had received two doses of SARS-CoV-2 mRNA vaccination and had undergone measurement of baseline anti-Müllerian hormone (AMH) concentration within the 12 months preceding their recruitment. AMH concentrations before and after vaccination were evaluated and compared. Results: Overall, 31 women were included in the study. The median AMH concentrations before and after COVID-19 vaccine were comparable (1.7 versus 1.6 g/ml, respectively, P = 0.96). No correlation was found between the participant's anti-COVID-19 antibody titre and the change in AMH concentration. Conclusions: SARS-CoV-2 mRNA vaccination does not adversely affect ovarian reserve, as shown by comparing serum AMH concentrations before and after vaccination. These findings may serve as a counselling tool for clinicians to reassure women undergoing fertility treatment that SARS-CoV-2 mRNA vaccination is safe.